WallStreetZenWallStreetZen

NYSEMKT: NAVB
Navidea Biopharmaceuticals Inc Earnings & Revenue

OverviewEarnings
DividendOwnership

NAVB past revenue growth

How has NAVB's revenue growth performed historically?
Company
-83.9%
Industry
69.53%
Market
14.01%
NAVB's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NAVB's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NAVB's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NAVB earnings and revenue history

Current Revenue
$65.7k
Current Earnings
-$15.7M
Current Profit Margin
-23,920.3%

NAVB Return on Equity

Current Company
N/A
Current Industry
-18%
Current Market
30.8%

Be the first to know when NAVB announces earnings.

NAVB Return on Assets

Current Company
-405.2%
Current Industry
0.9%
NAVB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NAVB Return on Capital Employed

Current Company
178.83%
Current Industry
14.1%
NAVB has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NAVB vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NAVB$65.65k-$12.12M-$15.70M-46.56%N/A
PBLA$0.00-$36.08M-$36.38MN/AN/A
HSTO$19.00k-$13.27M-$13.91M-78.15%N/A
DRMA$0.00-$9.13M-$9.06MN/AN/A
FWBI$0.00-$9.02M-$9.46MN/AN/A
View Top Biotech Stocks

Navidea Biopharmaceuticals Earnings & Revenue FAQ

What were NAVB's earnings last quarter?

On Invalid Date, Navidea Biopharmaceuticals (NYSEMKT: NAVB) reported Q1 2023 earnings per share (EPS) of -$0.05, up 50% year over year. Total Navidea Biopharmaceuticals earnings for the quarter were -$1.48 million. In the same quarter last year, Navidea Biopharmaceuticals's earnings per share (EPS) was -$0.10.

If you're new to stock investing, here's how to buy Navidea Biopharmaceuticals stock.

What was NAVB's earnings growth in the past year?

As of Q2 2023, Navidea Biopharmaceuticals's earnings has grown year over year. Navidea Biopharmaceuticals's earnings in the past year totalled -$15.70 million.

What was NAVB's revenue last quarter?

On Invalid Date, Navidea Biopharmaceuticals (NYSEMKT: NAVB) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Navidea Biopharmaceuticals's revenue was $0.00.

What was NAVB's revenue growth in the past year?

As of Q2 2023, Navidea Biopharmaceuticals's revenue has grown -83.9% year over year. This is 153.43 percentage points lower than the US Biotechnology industry revenue growth rate of 69.53%. Navidea Biopharmaceuticals's revenue in the past year totalled $65.65 thousand.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.